KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Pankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew Kuykendall, Francesca Palandri, John Mascarenhas, Haifa Al-Ali, Francesco Passamonti, Wayne Rothbaum, Srdan Verstovsek, Florian H Heidel

Future Oncol 22(7) 781-793

PMID41793151
PMCIDPMC12980654
DOI10.1080/14796694.2026.2638989
发表日期2026-03-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 flow diagram。
摘要

摘要

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is critical for MF patients, as both are associated with improved quality of life (QoL) and overall survival (OS). Navtemadlin is a potent, selective, oral MDM2 inhibitor that restores p53 activity, inducing apoptosis of malignant TP53 wild-type (TP53WT) CD34+ MF progenitor cells. In vitro and clinical data demonstrated navtemadlin's synergy with ruxolitinib and disease-modifying potential. POIESIS is a global, randomized, double-blind phase III trial (NCT06479135) evaluating navtemadlin versus placebo as add-on to ruxolitinib in JAK inhibitor-naïve TP53WT MF patients with suboptimal response to ruxolitinib. The study includes a ruxolitinib monotherapy run-in period, followed by randomization of suboptimal responders to add-on navtemadlin or placebo to their stable ruxolitinib dose. Study objectives are to isolate the contribution of add-on navtemadlin by assessing SVR and TSS 24-weeks after randomization from the pre-randomization baseline and to demonstrate that this contribution is clinically meaningful using established SVR and TSS endpoints from the pre-ruxolitinib treatment baseline. Secondary endpoints include progression-free survival, leukemia-free survival, and OS.Clinical Trial Registration: NCT06479135 (ClinicalTrials.gov); EUCT 2023-504724-25-00 (EUClinicalTrials.EU).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Week 24 spleen volume reduction (by central MRI/CT) and total symptom score (by MFSAF v4.0). Baseline spleen volume MRI/CT scans and TSS assessments were taken while subjects were on a stable dose of ruxolitinib for ≥8 weeks (ie, no ruxolitinib wash-out). No dose increases of ruxolitinib above the stable baseline dose occurred during the 24-week assessment period. Both SVR35 and TSS50 were 32% at Week 24. Median time on ruxolitinib monotherapy was 21.6 months (data cut-off May 2023; ref. [44]). *Six patients discontinued prior to Week 24 assessment.
非 KM Figure
Figure 2Figure 2. Reduction in circulating CD34 + MF progenitor cell counts in study KRT-232-109 (data cut-off April 2023 [44]). *One patient with a cell count of 0 at Week 24 not shown on this figure.
非 KM Figure
Figure 3Figure 3. POIESIS study schema.
非 KM Figure